Beacon Biosignals raises $27m for neurobiomarker platform

EEG

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

$27 million Series A led by General Catalyst will enable Beacon to scale its EEG neurobiomarker discovery platform.

Beacon Biosignals, a neurotechnology company applying AI to EEG (electroencephalography) has announced an oversubscribed $27m Series A financing led by General Catalyst and with participation from Casdin Capital. Proceeds will be used to scale Beacon’s computational biomarker discovery platform and address the massive unmet need for quantitative clinical trial endpoints, safety tools and computational diagnostics for neurology, psychiatry, and sleep medicine.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Seragy raises $13.4m for protein clumps

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE